- Advanced Proteome Therapeutics’ (APC) subsidiary has had its technology featured in a peer-reviewed publication
- The manuscript, titled “Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates” by Sarrett et al. was published in the prestigious journal, Bioconjugate Chemistry
- It will be available online and will be included in a forthcoming journal issue
- The collaboration looked at the company site-selective conjugation approach using the antibody pertuzumab
- Advanced Proteome Therapeutics (APC) is up over 60 per cent, trading at C$0.18 at 1:09 pm EST
Advanced Proteome Therapeutics’ (APC) subsidiary, Advanced Proteome Therapeutics, has had its technology featured in a peer-reviewed publication.
The manuscript entitled “Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates” by Sarrett et al. has been published in the prestigious journal Bioconjugate Chemistry.
Bioconjugate Chemistry is a peer-reviewed journal focused on bioconjugation published by the American Chemical Society.
The manuscript is available online and will be included in a forthcoming journal issue.
The publication represents the final results of the previously announced collaboration between APTI and the Zeglis lab at the City University of New York to investigate APTI’s site-selective conjugation in the rapidly growing field of radioimmunoconjugates (RICs).
The collaboration looked at the company’s site-selective conjugation approach using the antibody pertuzumab.
This antibody targets the HER2 receptor, which is overexpressed on many malignancies, including breast and gastric cancer.
The conjugates were tested in vitro for key characteristics, including stability and target binding and two in vivo models – BT-474 breast cancer and SKOV-3 ovarian cancer.
Some findings from the study were that radioconjugate was more than 99 per cent stable in human serum over five days.
It also showed that radioconjugate exhibited higher immunoreactivity (binding) to the HER2 receptor than the cysteine maleimide construct.
Dr. Benjamin Krantz, President and CEO of APTI, commented,
“I am thrilled by the publication of the results of our collaboration with the Zeglis lab in Bioconjugate Chemistry. Bioconjugate Chemistry is one of the most important journals in bioconjugation, and its publication there provides significant visibility to potential collaborators.”
Dr. Brian Zeglis added,
“The study showed that APTI’s radioimmunoconjugates exhibited exceptional in vitro and in vivo performance and were better-defined and more homogeneous than traditional methods.”
Advanced Proteome Therapeutics has invented proprietary protein conjugation technology enabling the development of superior antibody-drug conjugates through improved site-specific labelling drug-antibody ratio control and combination payloads.
Advanced Proteome Therapeutics (APC) is up over 60 per cent, trading at C$0.18 at 1:09 pm EST.
